The limbic system-associated membrane protein (LSAMP) is a cell adhesion molecule belonging to the immunoglobulin (Ig) superfamily, primarily expressed in the limbic system of the central nervous system (CNS), including regions like the hippocampus, amygdala, and cortex. It plays a critical role in neural development, axon guidance, and the formation of neuronal circuits, particularly in pathways associated with emotion, memory, and behavior. LSAMP interacts with extracellular matrix components and other IgCAMs to mediate cell-cell recognition and synaptic plasticity.
LSAMP antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to map LSAMP distribution in brain tissues or cultured neurons. Research has linked LSAMP dysregulation to neuropsychiatric disorders, including schizophrenia, depression, and autism spectrum disorders, as well as certain cancers, where it may act as a tumor suppressor.
These antibodies are often validated for specificity across species (e.g., human, rat, mouse) and tested for cross-reactivity. Commercial LSAMP antibodies typically target extracellular Ig-like domains or cytoplasmic regions, enabling diverse experimental applications. Recent studies also explore LSAMP's role in neural repair and as a biomarker, underscoring its therapeutic potential. Proper controls, such as knockout tissue samples, are recommended to confirm antibody reliability in LSAMP-related research.